Personalis CEO Christopher Hall Acquires 100,000 Shares
Christopher Hall, CEO of Personalis, Inc., purchased 100,000 shares on June 26, 2026, at $1.61 per share.
Key Points
- Christopher Hall, CEO of Personalis, Inc., bought 100,000 shares at $1.61 each on June 26, 2026, totaling $161,000.
- Shares of Personalis, Inc. traded near $13.02 on Saturday with a market cap of approximately $1.36 billion.
- Analysts have set price targets ranging from $9 to $13, with Morgan Stanley maintaining a hold rating as of May 12, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Christopher Hall, the CEO of Personalis, Inc. (NasdaqGM: PSNL), recently acquired 100,000 shares of the company, paying $1.61 per share in an unplanned transaction on June 26, 2026. This purchase amounted to a total value of $161,000.
Insider Buying and Selling at Personalis, Inc.
On the same day, Aaron Tachibana, the CFO and COO, also bought 51,251 shares at an average price of $7.48, although he later sold the same amount under a planned transaction at $13.18 per share. Hall himself executed a planned sell of 100,000 shares at $13.15 per share after his initial purchase. These transactions highlight active trading by top executives.
Personalis, Inc. Stock Down 23.7%
Shares of Personalis, Inc. traded near $13.02 on Saturday. The company, which specializes in advanced cancer genomic tests, has a market cap of about $1.36 billion. It has no meaningful forward P/E ratio due to its lack of profitability, with an EPS of -$1.02. The stock's 52-week range has been between $3.84 and $13.37, and it has a beta of 2.276, indicating higher volatility compared to the market.
$PSNL stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Morgan Stanley maintained its hold rating on Personalis with a $9 price target on May 12, 2026. BTIG reiterated its buy rating with a target of $11 on May 11, 2026, while Needham supports a buy rating with a $12 target. The consensus among analysts suggests a mean target price of $10.86, with seven analysts covering the stock.
About Personalis, Inc.
Personalis, Inc. is a healthcare company headquartered in Fremont, California. It develops and sells genomic tests and services, focusing on cancer diagnostics and research. The company provides a range of advanced testing services, including liquid biopsy tests for cancer detection and monitoring. With a workforce of 259, Personalis collaborates with pharmaceutical and diagnostics companies, as well as research institutions, to advance personalized cancer therapies.
Bottom Line
Christopher Hall's purchase of Personalis shares indicates his confidence in the company's future. Investors often track such insider transactions for potential signals about company prospects. However, it's important to remember that these actions can be part of broader strategic decisions and may not reflect the company's current performance. Personalis continues to operate in the competitive field of cancer genomics, with analysts offering varied price targets.
Get Personalis, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PSNL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.